6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4 Puritas >98.0% (LCMS) Ensitrelvir (S-217622) Intermedia COVID-19

Description:

Nomen: 6-Chloro-2-methyl-2H-indazol-5-amine

CAS: 1893125-36-4

Puritas: >98.0% (LCMS)

Aspectus: Lumen Brown ad Grey solidum pulveris

Medium Ensitrelvir (S-217622), COVID-19 .

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Ensitrelvir (S-217622) Intermedia:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl) -1-methyl-1H-1,2,4-triazolum hydrochloridum CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8

Chemical Properties:

Nomen chemicum	6-Chloro-2-methyl-2H-indazol-5-amine
CAS Number	1893125-36-4
CATTUS Number	RF-PI1506
Stock Status	In Stock
Formulae hypotheticae	C8H8ClN3
M. Pondus	181.62
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lumen Brown ad Grey solidum pulveris
Puritas / Analysis Methodus	>98.0% (LCMS)
1 H NMR Spectrum	Congruunt cum Structure
LCMS	Congruunt cum Structure
Damnum in Siccatio	≤1.00%
Totalis immunditias	<2.00%
Test Standard	Enterprise Standard
Consuetudinem	Medium Ensitrelvir (S-217622), COVID-19 .

Sarcina & Repono:

sarcina: Utrem, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

6-Chloro-2-methyl-2H-indazol-5-amine (CAS: 1893125-36-4) medium est Ensitrelvir (S-217622).Ensitrelvir auctore Shionogi & Co. est pharmacum antivirale valde efficax quod aeque ac Pfizer Paxlovid operatur.Oral Xocova (Ensitrelvir), quae eandem mechanismum actionis habet ac Pfizer's Paxlovid (Nirmatrelvir+Ritonavir), differt in eo quod semel in die accipi debet, dum therapeutica efficacia ensitrelviri non videtur minor esse Paxlovid.Monumentum Nirmatrelvir bis cotidie administratur una cum cursus a Ritonavir repraesentato.Ensitrelvir factus est primum pilum domesticum Iaponicum ad tractandum COVID-19, tertium in Iaponia regulariter approbatum;mense Februario MMXXII.